Clinical Research Details

Clinical Research

Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients with Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity

Study Description

To investigate the effects of evolocumab in addition to statin therapy on HPR rates and platelet reactivity in patients with atherosclerotic cardiovascular disease (ASCVD) and HPR while on clopidogrel treatment. Secondary aims will include the effects on cholesterol levels.

Patients will be randomly assigned to receive either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).

Open Enrollment

Contact Name: Hope Dover
Contact Phone: (904) 244-2682
Contact Email:


Principal Investigator
Dominick J. Angiolillo, M.D., Ph.D., FACC

Sub Investigator
Francesco Franchi, M.B.Ch.B. (M.D.)

Sub Investigator
Fabiana Rollini, M.B.Ch.B. (M.D.)